# **Special Issue**

# Radiopharmaceutical Chemistry and Radiotherapy

## Message from the Guest Editor

This Special Issue is related to recent developments in the field of radiopharmaceutical chemistry with a special emphasis on radiotherapy. As part of their clinical care, physicians recommend radiation therapy as primary, neo-adjuvant, adjuvant, or palliative treatments to more than half of all cancer patients. Radiation therapy uses the intense energy associated with ionizing radiation to destroy cancerous cells. This radiation can be administered from an external source, through brachytherapy, or by using the systemic circulation to deliver therapeutic radiopharmaceuticals, which are designed to exploit dysregulated physiological processes and protein overexpression that cancer cells use to survive. This Special Issue seeks to highlight the creative collaborations among researchers in the physical, biological, and health sciences that are conducting innovative preclinical or clinical radiotherapy research. All researchers working in the field are cordially invited to contribute original research papers or reviews to this Special Issue of *Molecules*.

## **Guest Editor**

Dr. Thaddeus J. Wadas

Department of Radiology, University of Iowa, Iowa City, IA 52242, USA

## Deadline for manuscript submissions

closed (15 April 2021)



## **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/24135

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules





# **Molecules**

an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.6 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

## **Editor-in-Chief**

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

### **Author Benefits**

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

## **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).

